Abstract:BACKGROUND:The serotonin receptor 1A and 1B (HTR1A/1B) gene have been suggested to be involved in the pathogenesis of major depressive disorder (MDD) and the antidepressant treatment response. Gene expression differences were partly mediated by genetic polymorphism and DNA methylation which might be affected by environmental factors. In the present study, we attempt to identify whether HTR1A/1B DNA methylation and genetic polymorphism could predict antidepressant treatment response.METHODS:85 Chinese Han MDD patients were clinically assessed 8 weeks after of initiating escitalopram treatment for the first time. Antidepressant treatment response was assessed by changes in the Hamilton Depression Rating Scale-17 items (HAMD-17) score. The Life Events Scale (LES) and the Childhood Trauma Questionnaire (CTQ) were utilized as the assessment of previous life stress. The Illumina HiSeq platform was used to assess DNA methylation at 96 CpG sites located in HTR1A and HTR1B gene promoter regions. Six single nucleotide polymorphisms (SNPs) (HTR1A rs6294, rs116985176; HTR1B rs6296, rs6298, rs1228814, rs1778258) were genotype by using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) or PCR sequencing. Regression analyses were used to explore the relationship between DNA methylation and SNP and antidepressant response.RESULTS:We identified two CpG sites predictor of antidepressant treatment response (CpG 668, amplicon HTR1A_1, NC_000005.10, P = 0.025; CpG 1401, amplicon HTR1B_4, NC_000006.12, P = 0.033). The interaction of four CpG sites hypomethylation of HTR1A/1B with high recent stress might result in impaired antidepressant treatment response. What's more, the present data indicated that age, environments and antidepressant treatment might affect DNA methylation status. It was found that DNA methylation status could be influenced by antidepressant treatment in turn. However, HTR1A and HTR1B genotypes did not influence antidepressant response and DNA methylation status.CONCLUSIONS:The results suggest that HTR1A/1B DNA hypomethylation and its interaction with recent life stress might drive impaired antidepressant treatment response. Meanwhile, DNA methylation, in turn, was modified by antidepressant treatment and environments. Our results offer new evidence for the role of epigenetic and genetic polymorphism in pharmacological response to antidepressants.

Pilot Study of Genome-Wide DNA Methylation and Gene Expression for Treatment Response to Escitalopram in Panic Disorder.

Integrated genome-wide methylation and expression analyses provide predictors of diagnosis and early response to antidepressant in panic disorder

Effects of Cytochrome P450 2C19 Genetic Polymorphisms on Responses to Escitalopram and Levels of Brain-Derived Neurotrophic Factor in Patients with Panic Disorder.

Effects of antidepressant on FKBP51 mRNA expression and neuroendocrine hormones in patients with panic disorder

Identification of early candidate urine biomarkers for measure Escitalopram treatment response from major depressive disorder

HTR1A/1B DNA Methylation May Predict Escitalopram Treatment Response in Depressed Chinese Han Patients.

A genome-wide association study of escitalopram treatment outcomes in patients with major depressive disorder

Integrative Genetic Variation, DNA Methylation, and Gene Expression Analysis of Escitalopram and Aripiprazole Treatment Outcomes in Depression: A CAN-BIND-1 Study

Epigenome-Wide DNA Methylation in Unipolar Depression: Predictive Biomarker of Antidepressant Treatment Response?

Predicting Escitalopram Monotherapy Response in Depression: the Role of Anterior Cingulate Cortex

Association of DNA Methylation in BDNF with Escitalopram Treatment Response in Depressed Chinese Han Patients

DNA methylation of serotonin genes as predictive biomarkers of antidepressant treatment response

A Panel of Mirnas is Involved in the Effect of Sertraline on Panic Disorder, As Implicated by a Microarray-Based Analysis

Anxiety Symptom Remission is Associated with Genetic Variation of PTPRZ1 among Patients with Major Depressive Disorder Treated with Escitalopram

Label-Free Liquid Chromatography–Mass Spectrometry Proteomic Analysis of the Urinary Proteome for Measuring the Escitalopram Treatment Response from Major Depressive Disorder

The Relationship of Peripheral Blood Single Uncoding RNA-25-3p Expression Level and the Sertraline Efficacy in Patients with Panic Disorder

Drug Response-Related DNA Methylation Changes in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder

Characterization of gut microbiome in mice model of depression with divergent response to escitalopram treatment.

Regional Brain Metabolism and Treatment Response in Panic Disorder Patients: An [18F]FDG-PET Study

Serum Metabolomic Profiling Revealed Potential Diagnostic Biomarkers in Patients with Panic Disorder

Modulation of neural oscillations in escitalopram treatment: a Canadian biomarker integration network in depression study